MedTrace Logo

A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004)

NCT07614984 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 750

Last updated 2026-05-29

No results posted yet for this study

Summary

Researchers designed a trial medicine called MK-7262 to lower levels of Lp(a) in the blood. Researchers want to learn about giving MK-7262 with another trial medicine called enlicitide (also known as MK-0616 or enlicitide decanoate). Enlicitide is in a group of medicines that lower the amount of low-density lipoprotein cholesterol (LDL-C).

The goals of this trial are to evaluate:

* if MK-7262 and enlicitide taken together work better than placebo at lowering Lp(a) and LDL-C levels in the blood
* if MK-7262 alone works better than placebo at lowering Lp(a) levels in the blood
* the safety and tolerability of taking MK-7262 and enlicitide alone and together

Conditions

  • Lipoprotein(a)

Interventions

DRUG

MK-7262

Oral Coated Tablet

DRUG

Enlicitide

Oral Coated Tablet

DRUG

Placebo for MK-7262

Oral Coated Tablet

DRUG

Placebo for enlicitide

Oral Coated Tablet

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-07
Primary Completion
2027-10-12
Completion
2027-10-12
FDA Drug
Yes

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07614984 on ClinicalTrials.gov